Literature DB >> 8394815

Safety and efficacy of lomefloxacin versus norfloxacin in the treatment of complicated urinary tract infections.

I M Hoepelman1, W H Havinga, R A Benne, M Zwinkels, M A de Wit, H A de Hond, T A Boon, M R Visser, F W van Asbeck, J Verhoef.   

Abstract

Seventy patients with complicated urinary tract infections were treated with either lomefloxacin (400 mg once daily) or norfloxacin (400 mg twice daily) for 10 to 14 days. A total of 19 (86%) of 22 patients treated with lomefloxacin and 20 (74%) of 27 patients treated with norfloxacin were cured, as defined by a negative culture five to nine days after completion of therapy (p = 0.09). After four to six weeks, the figures were 56% for lomefloxacin and 48% for norfloxacin. Adverse effects in the lomefloxacin group were observed on 20 occasions in 12 patients (one stopped treatment) compared to nine occasions in five patients treated with norfloxacin (difference not significant).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8394815     DOI: 10.1007/bf01964430

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  14 in total

1.  Pharmacokinetics of lomefloxacin in renally compromised patients.

Authors:  R A Blum; R W Schultz; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

2.  Double-blind, dose-range-finding study of fleroxacin (RO 23-6240; AM-833) for treatment of complicated urinary tract infections.

Authors:  M J Wolfhagen; A I Hoepelman; J Verhoef
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

Review 3.  Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A N Wadworth; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

4.  Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis.

Authors:  T Sandberg; G Englund; K Lincoln; L G Nilsson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-05       Impact factor: 3.267

Review 5.  Norfloxacin: a new targeted fluoroquinolone antimicrobial agent.

Authors:  J S Wolfson; D C Hooper
Journal:  Ann Intern Med       Date:  1988-02       Impact factor: 25.391

6.  Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin.

Authors:  W R Bowie; V Willetts; P J Jewesson
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

7.  Norfloxacin versus parenteral therapy in the treatment of complicated urinary tract infections and resistant organisms.

Authors:  C Cherubin; S Stilwell
Journal:  Scand J Infect Dis Suppl       Date:  1986

8.  A double-blind comparison of low-dose ofloxacin and amoxycillin/clavulanic acid in acute exacerbations of chronic bronchitis.

Authors:  C M Rademaker; A P Sips; H M Beumer; I M Hoepelman; B P Overbeek; M J Möllers; M Rozenberg-Arska; J Verhoef
Journal:  J Antimicrob Chemother       Date:  1990-11       Impact factor: 5.790

9.  In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones.

Authors:  N X Chin; A Novelli; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

10.  Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function.

Authors:  A Leroy; J P Fillastre; G Humbert
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

View more
  4 in total

Review 1.  Pharmacokinetic characteristics of antimicrobials and optimal treatment of urosepsis.

Authors:  Florian M E Wagenlehner; Wolfgang Weidner; Kurt G Naber
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 2.  A practical guide to the management of complicated urinary tract infection.

Authors:  L E Nicolle
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

Review 3.  A practical guide to antimicrobial management of complicated urinary tract infection.

Authors:  L E Nicolle
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 4.  Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections.

Authors:  Culley Carson; Kurt G Naber
Journal:  Drugs       Date:  2004       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.